axinn

Axinn Granted Summary Judgment in Delaware Federal Court

NEWS | LESS THAN 1 MIN READ

June 24, 2014 Law360

A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.

Click <u>here</u> to read about the judgment in *Law360's* article.

Related People



Thomas K. Hedemann

Related Services

To subscribe to our publications, click here.

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
 SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
 SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum EVENT
- SABA North America Corporate Counsel Retreat 2025 SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
 CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
 AWARDS & RECOGNITIONS
 ANTITRUST
- Merger Remedies Back in Vogue Under Trump
 MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

 A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved